prikaz prve stranice dokumenta Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
  Download
PDF 1.05 MB
Professional paper - Professional paper
Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
Journal of the European Academy of Dermatology and Venereology, 36 (2022), 10; 1689-1704. https://doi.org/10.1111/jdv.18220
Borradori, L.; Van Beek, N.; Feliciani, C.; Tedbirt, B.; Antiga, E.; Bergman, R.; Böckle, B. C.; Caproni, M.; Caux, F.; Chandran, N.S.; Cianchini, G.; Daneshpazhooh, M.; De, D.; Didona, D.; Di Zenzo, G. M.; Dmochowski, M.; Drenovska, K.; Ehrchen, J.; Goebeler, M.; Groves, R.; Günther, C.; Horvath, B.; Hertl, M.; Hofmann, S.; Ioannides, D.; Itzlinger‐Monshi, B.; Jedličková, J.; Kowalewski, C.; Kridin, K.; Lim, Y. L.; Marinović, Branka; Marzano, A. V.; Mascaro, J.‐M.; Meijer, J.M.; Murrell, D.; Patsatsi, K.; Pincelli, C.; Prost, C.; Rappersberger, K.; Sárdy, M.; Setterfield, J.; Shahid, M.; Sprecher, E.; Tasanen, K.; Uzun, S.; Vassileva, S.; Vestergaard, K.; Vorobyev, A.; Vujic, I.; Wang, G.; Wozniak, K.; Yayli, S.; Zambruno, G.; Zillikens, D.; Schmidt, E.; Joly, P. More authors...

Cite this document

Borradori, L., Van Beek, N., Feliciani, C., Tedbirt, B., Antiga, E., Bergman, R. ... Joly, P. (2022). Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology, 36. (10), 1689-1704. doi: 10.1111/jdv.18220

Borradori, L., et al. "Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)." Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 10, 2022, pp. 1689-1704. https://doi.org/10.1111/jdv.18220

Borradori, L., N. Van Beek, C. Feliciani, B. Tedbirt, E. Antiga, R. Bergman, B. C. Böckle, et al. "Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)." Journal of the European Academy of Dermatology and Venereology 36, no. 10 (2022): 1689-1704. https://doi.org/10.1111/jdv.18220

Borradori, L., et al. (2022) 'Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)', Journal of the European Academy of Dermatology and Venereology, 36(10), pp. 1689-1704. doi: 10.1111/jdv.18220

Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, and sur.. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology [Internet]. 2022 October [cited 2025 February 23];36(10):1689-1704. doi: 10.1111/jdv.18220

L. Borradori, et al., "Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)", Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 10, pp. 1689-1704, October 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:834756. [Accessed: 23 February 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)
AuthorL. Borradori
AuthorN. Van Beek
AuthorC. Feliciani
AuthorB. Tedbirt
AuthorE. Antiga
AuthorR. Bergman
AuthorB. C. Böckle
AuthorM. Caproni
AuthorF. Caux
AuthorN.S. Chandran
AuthorG. Cianchini
AuthorM. Daneshpazhooh
AuthorD. De
AuthorD. Didona
AuthorG. M. Di Zenzo
AuthorM. Dmochowski
AuthorK. Drenovska
AuthorJ. Ehrchen
AuthorM. Goebeler
AuthorR. Groves
AuthorC. Günther
AuthorB. Horvath
AuthorM. Hertl
AuthorS. Hofmann
AuthorD. Ioannides
AuthorB. Itzlinger‐Monshi
AuthorJ. Jedličková
AuthorC. Kowalewski
AuthorK. Kridin
AuthorY. L. Lim
AuthorBranka Marinović
AuthorA. V. Marzano
AuthorJ.‐M. Mascaro
AuthorJ.M. Meijer
AuthorD. Murrell
AuthorK. Patsatsi
AuthorC. Pincelli
AuthorC. Prost
AuthorK. Rappersberger
AuthorM. Sárdy
AuthorJ. Setterfield
AuthorM. Shahid
AuthorE. Sprecher
AuthorK. Tasanen
AuthorS. Uzun
AuthorS. Vassileva
AuthorK. Vestergaard
AuthorA. Vorobyev
AuthorI. Vujic
AuthorG. Wang
AuthorK. Wozniak
AuthorS. Yayli
AuthorG. Zambruno
AuthorD. Zillikens
AuthorE. Schmidt
AuthorP. Joly
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Dermatology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Dermatovenerology
Abstract (english)
Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo-like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. ----- Objectives and methodology: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence-based or rely on expert opinion. The degree of consent among all task force members was included. ----- Results: Treatment depends on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B-cell-depleting therapy and intravenous immunoglobulins may be considered in treatment-resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. ----- Conclusions: The guidelines for the management of BP were updated. They summarize evidence- and expert-based recommendations useful in clinical practice.
Keywords (english)
Languageenglish
Publication typeProfessional paper - Professional paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of the European Academy of Dermatology and Venereology
Numberingvol. 36, no. 10, pp. 1689-1704
p-ISSN0926-9959
e-ISSN1468-3083
DOIhttps://doi.org/10.1111/jdv.18220
URN:NBNurn:nbn:hr:105:834756
Publication2022-10
Document URLhttps://onlinelibrary.wiley.com/doi/10.1111/jdv.18220
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2022-11-16 12:32:05